Demand exists for treatments capable of preventing and reversing bone loss. Osteoporosis affects approximately six million people in Germany, primarily women, and is associated with aging and menopause. Current treatments possess limitations, prompting research into new bone-strengthening methods and biological targets.
New Target Identified: GPR133 Receptor
A study from Leipzig University has identified GPR133, an adhesion G protein-coupled receptor (GPCR), as a potential target. GPCRs transmit signals that regulate various bodily processes, though this specific subgroup is less studied. Research indicates that GPR133 is instrumental in bone formation and maintenance.
GPR133's Role in Bone Strength
Studies involving mice with genetic alterations affecting GPR133 exhibited low bone density early in life, similar to human osteoporosis. Professor Ines Liebscher, lead investigator, stated that a substance named AP503, identified via computer-assisted screening as a GPR133 stimulator, significantly increased bone strength in both healthy and osteoporotic mice.
AP503 and Bone Remodeling
Bone undergoes continuous renewal through osteoblasts (bone-building cells) and osteoclasts (bone-breaking cells). A balance between these cell types is essential for healthy bones.
The research indicates that GPR133 regulates this balance. The receptor is activated by interactions between bone cells and physical forces.
Activation triggers signals that enhance osteoblast activity and reduce osteoclast activity, resulting in stronger bone.
AP503 appears to mimic this natural activation, promoting bone formation and limiting bone breakdown. This positions AP503 as a promising candidate for future treatments, potentially for both bone protection and rebuilding in individuals with osteoporosis, including postmenopausal women.
Broader Health Implications: Bone and Muscle
Previous research by the same team showed that activating GPR133 with AP503 also improved skeletal muscle strength. Dr. Juliane Lehmann, lead author, noted that the parallel strengthening of bone and muscle highlights the receptor's potential for medical applications in aging populations.
Maintaining muscle and bone strength reduces risks of falls, fractures, and loss of independence in older adults.
The research team is conducting further studies on AP503 and GPR133 to explore its utility in other conditions and understand its overall function.
A Decade of Research Paves the Way
This discovery results from over a decade of research at Leipzig University focused on adhesion GPCRs, part of Collaborative Research Centre 1423.
Osteoporosis is often asymptomatic until a fracture occurs. Identifying GPR133 as a bone strength regulator introduces a new treatment direction.
Future therapies could aim to actively rebuild and restore bone strength, moving beyond solely slowing bone loss.
Further research is necessary before AP503 or similar compounds are evaluated in humans; however, the findings suggest a future where maintaining strong bones throughout life may be more achievable.